Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Biolosion
- Development stage
- Phase 2
- Lead developer
- Sun Yat-sen University
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Biolosion is a compound probiotic preparation developed by Guangzhou Biolosion Biotechnology, currently being evaluated in Phase II clinical trials as an adjunctive therapy for advanced urothelial carcinoma and triple-negative breast cancer (TNBC). As a live biotherapeutic product (LBP), it is designed to modulate the gut microbiome, which plays a critical role in regulating systemic immune responses and influencing the efficacy of oncology treatments like immune checkpoint inhibitors (ICIs) and neoadjuvant chemotherapy. The goal of Biolosion administration is to optimize the intestinal microbial environment to improve patient outcomes, increase response rates to standard-of-care therapies, and potentially reduce treatment-related toxicities.
- Brand names
- Biolosion
- Other names
- Biolosioncompound probiotic preparation Biolosionprobiotics compound Biolosion
Beyond the preview
Go deeper on Biolosion.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biolosion.